Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ayala Gover-Proaktor"'
Publikováno v:
HemaSphere, Vol 7, p e95758de (2023)
Externí odkaz:
https://doaj.org/article/042308bab93744f988b83793c5110d87
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S286-S287
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d641ff561e76df1ccee305fee207f5c7
https://doi.org/10.1016/s2152-2650(22)01362-3
https://doi.org/10.1016/s2152-2650(22)01362-3
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc16c44c7fa418c814f2107597246941
https://doi.org/10.1016/s2152-2650(22)00890-4
https://doi.org/10.1016/s2152-2650(22)00890-4
Autor:
Oren Pasvolsky, Avi Leader, Galit Granot, Ayala Gover-Proaktor, Oshrat Raz, Saar Shapira, Pia Raanani, Metsada Pasmanik-Chor
Publikováno v:
Leukemia & Lymphoma. 60:189-199
The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d555b17d2b70c2b772b1a6006c5d0ec8
https://doi.org/10.1080/10428194.2018.1466294
https://doi.org/10.1080/10428194.2018.1466294
Autor:
Galit Granot, Saar Shapira, Ayala Gover-Proaktor, Pia Raanani, Aida Inbal, Oren Pasvolsky, Arnon Nagler, Ido Lubin, Oshrat Raz, Avi Leader, Dorit L. Lev
Publikováno v:
Leukemia & Lymphoma. 58:1455-1467
Tyrosine kinase inhibitors (TKIs) have revolutionized the prognosis of chronic myeloid leukemia. With the advent of highly efficacious therapy, the focus has shifted toward managing TKI adverse effects, such as vascular adverse events (VAEs). We used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219259782e5e19a147edfc5b31bbdf0d
https://doi.org/10.1080/10428194.2016.1239258
https://doi.org/10.1080/10428194.2016.1239258
Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study
Autor:
Galit Granot, Ido Lubin, Saar Shapira, Oren Pasvolsky, Arnon Nagler, Avi Leader, Ayala Gover-Proaktor, Pia Raanani
Publikováno v:
Blood. 126:2798-2798
The introduction of several tyrosine kinase inhibitors (TKIs) into the armamentarium of chronic myeloid leukemia (CML) treatment has revolutionized the prognosis of this disease, changing it from a fatal one into a potentially curable disease. Five T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d981717081ff0367e1a194ef21f0ef
https://doi.org/10.1182/blood.v126.23.2798.2798
https://doi.org/10.1182/blood.v126.23.2798.2798